Researchers outlined positive data for two of the most advanced migraine drugs in development, from Teva and a Novartis-Amgen partnership, reinforcing the promise of a new class of treatment for the debilitating headaches.
from WSJ.com: US Business http://ift.tt/2ngSJRl
via IFTTT
No comments:
Post a Comment